Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RHEB | Q15382 | 2/20 | 0.31 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.31 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.31 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7873402 | 0.87 | RHEB (0.34) | RHEBCHEK2 | |
| SCHEMBL7877937 | 0.86 | MAPK14 (0.37) | RHEBLGALS8CHEK2 | |
| SCHEMBL7873782 | 0.85 | MEN1 (0.38) | CHEK2KDM4EALDH1A1 | |
| SCHEMBL7881811 | 0.85 | LMNA (0.31) | LGALS8LGALS3CHEK2KDM4EALDH1A1 | |
| SCHEMBL7879699 | 0.84 | MEN1 (0.41) | RHEBLGALS8LGALS3CHEK2KDM4E | |
| SCHEMBL7873656 | 0.84 | BRAF (0.33) | CHEK2KDM4EALDH1A1MAPT | |
| SCHEMBL7873184 | 0.84 | RHEB (0.38) | RHEBCHEK2 | |
| SCHEMBL7884778 | 0.84 | F10 (0.38) | RHEBLGALS8LGALS3ALDH1A1MAPT | |
| SCHEMBL7873369 | 0.83 | RHEB (0.34) | RHEBKDM4E | |
| SCHEMBL7878230 | 0.82 | SIRT2 (0.34) | RHEBLGALS8LGALS3CHEK2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6248772-B1 | HYPOTENSIVE AGENTS; ANTIARRHYTHMIA AGENTS; ANTIDIABETIC AGENTS; ANTIPROLIFERATIVE AGENTS | SUMITOMO PHARMACEUTICALS CO., LTD. (JP) | 2001-06-19 | — | — | US | disclosed |
| US-6169107-B1 | USEFUL FOR THE TREATMENT AND PREVENTION OF DISEASES CAUSED BY INCREASED SODIUM/PROTON (NA.SUP.+ /H.SUP.+) EXCHANGER ACTIVITY, FOR EXAMPLE, HYPERTENSION, ARRHYTHMIA, ANGINA PECTORIS, CARDIAC HYPERTROPHY, DIABETES MELLITUS | SUMITOMO PHARMACEUTICAL CO., LTD. (JP) | 2001-01-02 | — | — | US | disclosed |
| EP-0708091-A2 | Indoloylguanidine derivatives | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1996-04-24 | — | — | EP | disclosed |